12:00 AM
Jan 05, 2009
 |  BC Week In Review  |  Company News  |  Deals

Cytokinetics, GlaxoSmithKline deal

GlaxoSmithKline will not exercise its option to license ispinesib and SB-743921 from Cytokinetics under a 2001 deal. GSK said the decision not to license the kinesin spindle protein ( KSP) inhibitors was due to a "shift in...

Read the full 179 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >